公开(公告)号：US20200237669A1

公开(公告)日：2020-07-30

申请号：US16628530

申请日：2018-07-06

Applicant: KYOTO PHARMACEUTICAL UNIVERSITY

Inventor： Hidemasa Katsumi ,  Akira Yamamoto

IPC: A61K9/14 ,  A61K31/401 ,  A61K47/60 ,  A61P13/12

Abstract: The present invention relates to a compound having a macromolecular carrier having a plurality of terminal groups, wherein the carbonyl group of serine is linked by a peptide bond or an ester bond directly or via a linker to the terminal groups, a carrier for drug delivery composed of the compound, and a medicament for preventing or treating renal diseases, containing the carrier for drug delivery and a drug bonded to the carrier directly or via a linker or encapsulated therein. According to the present invention, a carrier for drug delivery that is selectively accumulated in kidney in vivo can be provided.

公开(公告)号：US20220362278A1

公开(公告)日：2022-11-17

申请号：US17624112

申请日：2020-07-01

Applicant: KYOTO PHARMACEUTICAL UNIVERSITY

Inventor： Hidemasa Katsumi ,  Akira Yamamoto

IPC: A61K31/7088 ,  A61K49/00 ,  A61K47/42 ,  A61K47/64 ,  A61P13/12

Abstract: The present invention aims to provide a carrier for drug delivery that selectively accumulates in the kidney in the body, and shows high biodegradability and drug releasability in the kidney. The present invention relates to a compound in which a carbonyl group of serine is linked directly or via a linker to terminal amino group of linear polylysine, compound carrier for delivery, and a medicament for the diagnosis, prophylaxis, or treatment of a renal disease, containing the carrier for drug delivery, and a drug bound to the carrier directly or via a linker or encapsulated therein.

公开(公告)号：US10550153B2

公开(公告)日：2020-02-04

申请号：US16478966

申请日：2018-01-19

Applicant: Tokyo University of Pharmacy & Life Sciences ,  National Cerebral and Cardiovascular Center ,  Kyoto Pharmaceutical University

Inventor： Yoshio Hayashi ,  Kentaro Takayama ,  Mikiya Miyazato ,  Kenji Kangawa ,  Kenji Mori ,  Akira Yamamoto ,  Toshiyasu Sakane

IPC: A61K38/03 ,  C07K7/06 ,  A61P3/04 ,  A61K38/00

Abstract: To provide a peptide that selectively activates type 2 neuromedin U receptor and is chemically stable under physiological conditions. A peptide represented by Formula (1) described in the specification.